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Abstract
AIM
To evaluate how mucosal bacteria impact on the 
spontaneous and muramyl dipeptide (MDP)-induced 
inflammation in Crohn’s disease (CD) and ulcerative 
colitis (UC).
METHODS
Colonic mucosal biopsies were collected from children 
with active or remissive CD, UC and controls. Two 
tissue samples were taken from inflamed mucosal 
segments (in patients with active disease) or from non-
inflamed mucosa [in patients in remission or in healthy 
controls (HC)]. Experiments were performed in the 
presence or absence of antibiotics, to assess whether 
the disease-associated microbiota can modulate the 
cytokine response ex vivo . For this purpose, each 
specimen was half-cut to compare spontaneous and 
MDP-induced inflammation in the presence of live 
bacteria (LB) or antibiotics. After 24 h of culture, an 
array of 17 cytokines was assessed in supernatants. 
Statistical analyses were performed to find significant 
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differences in single cytokines or in patterns of cytokine 
response in the different groups. 
RESULTS
We demonstrated that subjects with CD display a 
spontaneous production of inflammatory cytokines 
including granulocyte-colony stimulating factor (G-CSF), 
interleukin (IL) 6, IL8, IL10 and IL12, that was not 
significantly influenced by the addition of antibiotics. 
UC specimens also displayed a trend of increased 
spontaneous secretion of several cytokines, which 
however was not significant due to broader variability 
among patients. After the addition of antibiotics, 
spontaneous IL8 secretion was significantly higher in UC 
than in controls. In HC, a trend towards the weakening 
of spontaneous IL8 production was observed in the 
presence of live mucosal bacteria with respect to the 
presence of antibiotics. In contrast, in the presence of 
LB UC showed an increasing trend of spontaneous IL8 
production, while MDP stimulation resulted in lower 
IL8 production in the presence of antibiotics. We also 
showed that subjects with CD seem to have a lowered 
production of IL8 in response to MDP in the presence of 
LB. Only with the addition of antibiotics, likely reducing 
the contribution of LB, multivariate statistical analysis 
could identify the combination of measures of G-CSF, 
tumor necrosis factor alpha, IL4 and IL17 as a good 
discriminator between CD and UC.
CONCLUSION
We showed that the presence of LB or antibiotics can 
significantly influence the inflammatory response ex 
vivo  in inflammatory bowel diseases. 
Key words: Gut-microbiota; Crohn’s disease; Ulcerative 
colitis; Cytokines; Inflammation
© The Author(s) 2016. Published by Baishideng Publishing 
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Core tip: Even though previous studies have already 
considered cytokine secretions as marker of an infla-
mmatory condition and mucosal imbalance in Crohn’s 
disease (CD) subjects, they did not take into account 
the autochthonous colonization of the intestinal mucosa 
by the disease-associated microbiota. In this work we 
investigated whether the microbiota can modulate the 
ex vivo  cytokine response, in the presence or absence 
of antibiotics, or if a selection of cytokines could dis-
criminate different inflammatory bowel diseases types. 
Through a multivariate logistic model we identified, 
only in specimens treated with antibiotics, a specific 
cytokine profile able to discriminate CD from ulcerative 
colitis. 
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INTRODUCTION
Inflammatory bowel diseases (IBD) are intestinal 
disorders characterized by a complex inflammatory 
process that may involve any part of the digestive tract. 
IBD include mainly Crohn’s disease (CD) and ulcerative 
colitis (UC), which are characterized by a different 
spectrum of clinical and pathological features[1,2].
In CD, the inflammation is extended through the 
whole intestinal wall of the gut with a segmental 
distribution, while in UC the inflammatory process is 
continuous and predominantly confined to the colonic 
mucosa[2].
IBD are characterized by an aberrant activation of 
the mucosal immune system with reaction to luminal 
content in genetically susceptible subjects[3], resulting 
in a chronic inflammatory state with dysregulation of 
several cytokines[4-6]. 
Cytokines are important mediators in the gut-
associated immune system, both in physiological 
conditions and in disease[7]. In normal conditions, the 
mucosal immune activation reflects an active balance 
between tolerance of luminal content and response 
to commensal and pathogenic bacteria. Indeed, this 
basal activation is associated with a predominance of 
cytokines such as interleukin (IL) 10 and transforming 
growth factor beta and the production of antimicrobial 
peptides that can contribute to the shaping of the 
“healthy” microbiota. In pathological conditions, other 
cytokines and mediators are produced, which can, 
at the same time, lead to tissue injury and altered 
regulation of the microbiota and dysbiosis[4,8-10].
Chronic tissue damage results in clinical intestinal 
symptoms in IBD patients (abdominal cramping and 
pain, diarrhea, constipation and bowel obstruction, 
nausea and vomiting), even though extra-intestinal 
manifestations (weight loss, fever, asthenia and 
arthralgias) and immune disorders are also associated 
with this pathologies[11].
Despite the large number of studies and clinical 
analyses, several issues remain to be solved regard-
ing the immune pathogenesis of IBD. In particular, 
the therapy of IBD is still based mainly on anti-infla-
mmatory and immunosuppressive therapies, while 
mounting evidence supports the idea that defective 
immunity may underlie IBD pathogenesis, especially 
in cases with an early onset in childhood[12]. In fact, 
excessive inflammation in IBD could either result from 
a hyper-response of the immune system or it may just 
represent a compensatory response to luminal contest 
in the background of defective immunity[13].
Indeed, CD has been alternatively classified as an 
autoinflammatory disorder or a disease with primary 
immune deficiency[14].
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On the one hand, some studies suggested that 
CD is an autoinflammatory disease, characterized 
by an increase in the inflammatory response due to 
nucleotide-binding oligomerization domain-containing 
protein 2 (NOD2) variants, even though data su-
pporting this hypothesis are controversial. NOD2 is 
an intracellular receptor involved in gastrointestinal 
immunity; it detects bacterial components and has 
been identified as the first susceptibility gene for 
CD[15-17]. The binding of muramyl dipeptide (MDP) to 
NOD2 leads to the downstream activation of mitogen-
activated protein kinases and nuclear factor-kappa 
beta (NF-κB) signaling, which in turn stimulates the 
transcription of several immune response genes. 
However, early studies have shown the association of 
the most common mutation 3020insC with a reduced 
activation of NF-κB[18]. In contrast, later investigations 
proposed that the pro-inflammatory action is caused 
by a dysregulated autophagy[19].
On the other hand, several studies have found 
evidence that CD patients present immune response 
defects. In fact, a decreased bacterial clearance by the 
phagocytic system has been observed in peripheral 
blood cells from patients with CD; furthermore, 
NOD2-/- mice exhibit a reduced production of anti-
microbial peptides by Paneth cells that leads to an 
imbalance in the microbiota in the presence of certain 
microbial pathogens, and intestinal inflammation can 
be prevented in these models by the forced expression 
of defensins in the intestinal cells[20].
For these reasons, we wanted to describe what 
happens in the disease itself, not by using simple animal 
models, but by studying the relationships between the 
mucosal immune system, influenced by its multigenic 
background, and the intestinal microbiota colonizing the 
diseased epithelium. 
In these conditions, we tried to understand how 
the inflammatory response to stimuli such as MDP is 
influenced ex vivo by the presence of live or antibiotic-
inactivated bacteria. 
We performed an ex vivo culture of colonic explants 
to investigate the mucosal response both in spon-
taneous conditions and after the stimulation with MDP.
MATERIALS AND METHODS
Patients and gut biopsies collection
Forty-eight children with IBD and eight control subjects 
were enrolled. Participation in the study was proposed 
to all patients with IBD or their guardians when the 
performance of a colonoscopy was needed for clinical 
assessment, required for the diagnosis or the follow-up 
of their intestinal disease.
Patients with IBD were divided into four groups 
based on the type of intestinal disorder and on endo-
scopic mucosal disease activity: active Crohn’s disease 
(CD, n = 23), remissive Crohn’s disease (rCD, n = 3), 
active ulcerative colitis (UC, n = 15) and remissive 
ulcerative colitis (rUC, n = 7). Disease activity scores, 
namely the Pediatric Crohn’s Disease Activity Index 
and the Pediatric Ulcerative Colitis Activity Index were 
also calculated. Any other recent acute disease or 
chronic inflammatory conditions are reported in these 
patients.
Control subjects were selected among children 
who underwent colonoscopy as part of their clinical 
investigations for various reasons not related to 
inflammatory enteropathies, such as routine evaluation 
of juvenile intestinal polyps, autoimmune gastritis, 
unexplained abdominal symptoms and weight loss. 
They had evidence of normal, non-inflamed mucosa 
and were thus considered healthy controls (HC).
Colonic mucosal biopsies were taken during colono-
scopy. For each subject, two specimens were collected 
from the same mucosal area, in addition to the 
biopsies obtained for clinical purposes. In patients with 
active disease, two inflamed biopsies were collected, 
while in patients with inactive disease or HC two 
biopsies were taken from non-inflamed areas.
All subjects were recruited from the Gastro-
enterology and Clinical Nutrition Unit, Institute for 
Maternal and Child Health - IRCCS “Burlo Garofolo”, 
Trieste, Italy and written informed consent was obtained 
from patients and donors (or their guardians) according 
to a protocol approved by the Independent Ethical 
Board at the Institute (n.185/08, 19/08/2008).
Ex vivo specimen culture
Immediately after collection, biopsies were cut in half 
following the intestinal layers’ orientation and split in 
two tubes containing a physiological saline solution. 
Once they reached the laboratory, the specimens 
were transferred to sterile tubes with culture medium 
(X-VIVO, Lonza, Verviers, Belgium) supplemented with 
10% human AB serum (Sigma-Aldrich, Milano, Italy) 
and 2 mmol/L L-glutamine (EuroClone, Milano, Italy). 
The intestinal tissue was exposed to 250 ng/mL MDP 
(N-Acetylmuramyl-L-alanyl-D-isoglutamine hydrate, 
Sigma-Aldrich) or medium alone, in the presence or 
absence of antibiotics: 100 U/mL penicillin (EuroClone) 
and 0.1 mg/mL streptomycin (EuroClone).
After 24 h culture at 37 ℃ in a humidified atmo-
sphere (95% air and 5% CO2), supernatants were 
collected and stored at -20 ℃ for cytokine analysis.
Cytokine quantifications
The cytokines and the chemokines released in the 
culture medium were measured using the Bio-Plex 
Pro® Human Cytokine 17-plex Assay (BioRad, Hemel 
Hempstead, United Kingdom), according to the 
manufacturer’s instructions.
Analytes examined by this method were IL1β, IL2, 
IL4, IL5, IL6, IL7, IL8, IL10, IL12 (p70), IL13, IL17, 
granulocyte-colony stimulating factor (G-CSF), GM-
CSF, IFNγ, MCP1 (MCAF), MIP1β, and TNFα.
Samples were analyzed with the Bio-Plex® 200 
reader and data were managed using Bio-Plex Manager® 
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RESULTS
Experimental design
Clinical characteristics of all patients included in the 
study, obtained from the medical sheets and from the 
colonoscopy records, are reported in Supplementary 
Table 1 and Supplementary Table 2 and summarized in 
Table 1.
Ex vivo culture of biopsies is thought to repro-
duce both the immunological and the microbiologic 
background of the disease. However, to isolate the 
contribution of live bacteria (LB) to inflammation, 
biopsies were stimulated in absence or in presence of 
antibiotics. Thus, for each sample we examined four 
conditions: basal with LB or with antibiotics (PS), and 
MDP-stimulated with (PS + MDP) or without antibiotics 
(LB + MDP). 
After a 24 h culture, the media were harvested 
to proceed with the quantification of 17 analytes, 
including cytokines, chemokines and growth factors 
(Figure 1). 
The levels of three cytokines (IL5, IL7 and IL13) 
were under the lower limit of detection in all evaluated 
conditions and were thus excluded. 
Basal cytokine network in IBD
In basal conditions with live mucosal bacteria, five 
cytokines had levels significantly higher in CD than in 
controls (HC) (CD vs HC: G-CSF, P = 0.024, IL6 P = 
0.037, IL8 P = 0.033, IL10 P = 0.049, IL12, P = 0.028); 
levels of most cytokines tended to be even higher in 
UC, but because of the high variability among patients, 
differences did not reach significance, except for GM-
CSF, whose levels were higher in UC compared with 
both HC (P = 0.031) and CD (P = 0.034) (Figure 2).
Levels of IL1β, IL2, IL4, IL17, IFNγ, TNFα, MCP1 
and MIP1β did not differ significantly between the 
three studied groups, even if median levels of several 
cytokines such as IL2, IL4 and TNFα tended to be higher 
in UC than in HC. In general, HC showed a narrower 
variability compared to patients (Supplementary Figure 
1).
Median levels of all cytokines in the different groups 
and conditions are rendered in Figure 3 with a color 
analog scale (CAS): for each cytokine, values 0-24% 
of the higher value are displayed in green, 25%-49% 
in orange, 50%-74% in red and above 75% in dark 
red. 
In specimens from patients with endoscopically 
inactive disease, almost all cytokines were detected, 
as expected, at lower levels than in active disease. The 
decrease is significant in UC for GM-CSF (P < 0.01), 
IL6 (P < 0.05), IL10 (P < 0.05) and TNFα (P < 0.05) 
(Data not shown).
The addition of antibiotics in the bioptic culture 
to inhibit mucosal bacteria did not lead to relevant 
changes in the secretion pattern (Supplementary 
Figure 2), with the exception of IL8 in UC samples. 
software, which returned data as Median Fluorescence 
Intensity and concentration (pg/mL).
Statistical analysis
All statistical analyses were carried out using Stata/IC 
14.1 (StataCorp LP, College Station, United States) and 
GraphPad Prism software version 5 (GraphPad, San 
Diego, United States). Values assumed by cytokines 
were described as medians and interquartile ranges 
and represented with box plots using Tukey’s whiskers. 
Statistical significance was set as P < 0.05 (a), P < 0.01 
(b) and P < 0.001 (c).
Associations between cytokines and specific condi-
tions (HC vs IBD, and CD vs UC) were analyzed firstly 
by univariate logistic regression and then by multivariate 
logistic regression. For the multiple comparisons carried 
out by univariate logistic regression, considering the 
relatively small sample size, which implied having 
relatively large P values, we decided not to apply any 
correction to the P value for statistical significance: 
we realize that we carried out independent univa-
riate logistic regressions on different outcomes and 
separately for 17 cytokines, chemokines and growth 
factors. However, this just is considered as a preliminary 
step for the selection of cytokines to be included in 
the multivariate analysis: significant variables (P < 
0.05 in the univariate analysis) were entered into 
multivariate analysis. Multivariate logistic regression 
analysis was employed to determine cytokine profiles 
associated with the different forms of IBD. Receiver 
operating characteristic (ROC) curves were constructed 
to evaluate the performance of the multivariate 
models. The area under the curve (AUC), sensitivity and 
specificity were also calculated. For each model, we 
identified the optimal cut-off by maximizing the sum of 
sensitivity and specificity.
Table 1  Characteristics of patients included in the study
Patients 
(n  = 56)
Age (yr) 
(mean ± SD)
Male/female Active/
remission
IBD (n = 48)   CD (n = 26) 11 ± 3.08 16/10 23/3
  UC (n = 22) 15 ± 3.88 12/10 15/7
CONTROLS 
(n = 8)
HC (n = 8) 10 ± 4.60 4/4 -
IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative 
colitis; HC: Healthy controls.
Table 2  Multivariate logistic model for inflammatory bowel 
disease patients vs  healthy controls in the presence of 
antibiotics and without muramyl dipeptide stimulation
Variables OR 95%CI P  value Regression 
coefficients
IL2 1.553421 1.011162-2.386481 0.044  0.440460
IL4 0.473238 0.228780-0.978906 0.044 -0.748157
IL8 1.000267 1.000030-1.000504 0.027  0.000267
Constant 0.065259 0.003533-1.205600 0.067 -2.729393
Loganes C et al . Cytokine response in IBD
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The trend of IL8 increase after antibiotics in UC is so 
clear that the difference compared with HC becomes 
significant (Figure 4).
Cytokine network induced by MDP 
MDP was used to investigate the function of the NOD2-
pathway ex vivo in CD compared with UC and HC. 
In general, the response to MDP appeared to be 
higher in UC than in CD (see the CAS in Figure 3). 
After stimulation with MDP in the presence of LB, even 
though the differences are not significant, there is 
a clear trend of increased secretion of IL2, IL6, IL8, 
IL17 and IFNγ in UC, while no change was observed 
in CD. Indeed, even if in a smaller scale, HC tended to 
secrete reduced amounts of IL2, IL6 and IFNγ (Figure 
5).
However, after the addition of antibiotics, this 
pattern was subverted and MDP stimulation failed to 
produce an evident increase in cytokine secretion in 
any group and it was even possible to note a reduced 
trend of secretion for IL8 in UC (Figure 6). 
No variation was noted in the remaining cytokines, 
whose values are reported in supplementary Tables 3 
and 4. 
Multivariate logistic regression and ROC analysis 
to identify profiles of pro-inflammatory cytokines 
associated with IBD diagnosis
Multivariate logistic regression were carried out to 
assess if any cytokine combination was associated with 
IBD related outcomes. 
Only experiments in the presence of antibiotics 
provided profiles significantly associated with IBD. 
In particular, without MDP stimulation, IL2, IL4 and 
IL8 were simultaneously associated with IBD in a 
multivariate analysis (Table 2). ROC analysis (Figure 
7A) shows that the AUC was 0.98 (95%CI: 0.93-1.00), 
and we could have a sensitivity of 100% with a 
specificity of 71%. 
After MDP stimulation another set of cytokines 
(MCP1, IL8 and IL10) was significantly associated 
with IBD (Table 3). The AUC for this model was 0.91 
(95%CI: 0.79-1.00) (Figure 7B). Keeping sensitivity 
Two colonic biopsies from 
the same intestinal region
Cut of each biopsy  in half
 following the intestinal 
layers’ orientation
24 h culture at 37 ℃ 
of mucosal speciments 
with different stimuli
No stimulus
(LB)
+ Antibiotics
(PS)
+ MDP
 (LB + MDP)
+ Antibiotics + MDP
 (PS + MDP)
Collection of culture supernatants and
cytokine quantifications
Figure 1  Schematic culture protocol of colonic biopsies derived from colonoscopy. LB: Live Bacteria; PS: Penicillin-streptomicin; MDP: Muramyl dipeptide.
Table 3  Multivariate logistic model for inflammatory bowel 
disease patients vs  healthy controls in the presence of 
antibiotics and muramyl dipeptide stimulation
Variables OR 95%CI P  value Regression 
coefficients
MCP1 0.997248 0.995067-0.999434 0.014   -0.0027555
IL8 1.000094 1.000019-1.000170 0.014    0.0000944
IL10 1.098966 1.009008-1.196944 0.030    0.0943694
Constant 0.529026 0.108222-2.586054 0.432 -0.636717
Table 4  Multivariate logistic model for Crohn’s disease vs  
ulcerative colitis in the presence of antibiotics and muramyl 
dipeptide stimulation
Variables OR 95%CI P  value Regression 
coefficients
G-CSF 0.999703 0.999484-0.999921 0.008  -0.0002975
TNFα 0.990492 0.981420-0.999649 0.042  -0.0095533
IL4 1.155281 1.012918-1.317651 0.031   0.1443433
IL17 1.009361 1.000308-1.018497 0.043   0.0093177
Constant 1.043247 0.333344-3.264992 0.924 0.042338
Loganes C et al . Cytokine response in IBD
9739 November 28, 2016|Volume 22|Issue 44|WJG|www.wjgnet.com
for the detection of IBD at 94%, we obtained a 
specificity of 75%, which would permit to identify 45 
IBD patients out of 48, with 2 false positives out of 8 
HC.
After MDP stimulation it was also possible to discri-
minate between CD and UC based on the measure of 
G-CSF, TNFα, IL4 and IL17 (Table 4). According to the 
ROC analysis (Figure 7C), the AUC was 0.78 (95%CI: 
0.65-0.91), and we could obtain a sensitivity on CD of 
92.31% with a specificity of 50%.
DISCUSSION
It is well known that subjects with active IBD display 
increased secretion of several inflammatory cytokines in 
the intestinal mucosa. For example, aberrant secretions 
of IL8 after challenge with E. coli or other intestinal 
bacteria were recorded by Edward and colleagues 
and considered as a marker of the mucosal imbalance 
typical of CD[21]. The authors, however, did not take 
into account the autochthonous colonization of the 
intestinal mucosa by the disease-associated microbiota. 
In the present work, we compared the cytokine profile 
of the intestinal mucosa in the presence or absence 
of antibiotics, to assess whether disease-associated 
microbiota can modulate the cytokine response ex 
vivo. We demonstrated that subjects with CD display 
a spontaneous production of inflammatory cytokines 
besides IL8, and including G-CSF, IL6, IL10 and IL12. 
The addition of antibiotics to the culture produced 
only a slight trend towards increased spontaneous 
cytokine secretion, both in CD and in UC, but no 
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Figure 2  Cytokine secretion levels by colonic biopsies from inflammatory bowel diseases patients. Levels of cytokine secretion by colonic biopsies from 
inflammatory bowel diseases (IBD) patients in active phase [Crohn’s disease (CD); ulcerative colitis (UC)] and healthy controls (HC) in basal condition [live bacteria (LB)]. 
Statistical significances are denoted using alphabetical letters (aP < 0.05). 
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difference was significant, except for increased IL8 
secretion in UC. These data may support the idea that 
antibiotics can influence UC, as suggested by other 
authors[22]. However, whilst some protocols that include 
metronidazole in vivo are shown to have protective 
effects on disease activity[22], other combinations had 
no effect[23]. Actually, it is well known that the risk 
of CD can be raised by previous use of antibiotics in 
childhood, but this is not believed to occur for UC[24]. 
Thus, the significance of increased levels of IL8 in UC 
after the addition of antibiotics remains without a clear 
explanation.
Even if the difference is not significant, there is a 
trend toward higher concentrations of inflammatory 
cytokines in UC if compared to CD. Actually, this is 
not surprising if we consider that we are sampling 
just superficial specimens where UC is expected to 
be more expressed than CD, which, on the contrary, 
may extend the inflammatory process throughout the 
whole intestinal wall[25]. 
Of note, in HC, the IL8 secretion with or without 
MDP is reduced in the presence of LB if compared to 
antibiotics. This effect is likely due to a modulatory 
effect of LB on mucosal immunity. In contrast, samples 
from UC showed a trend of increase of cytokines 
such as IL6 and IL8 when stimulated with MDP in the 
presence of LB. However, in the presence of antibiotics, 
stimulation with MDP was associated with decreased 
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cytokines analyzed. Median levels of all cytokines in healthy controls (HC), 
Crohn’s disease (CD) and ulcerative colitis (UC) groups in the four experimental 
conditions: live bacteria (LB), antibiotics (PS), live bacteria + Muramyl dipeptide 
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Figure 4  Dosage of IL8 secretion by colonic biopsies from inflammatory 
bowel diseases patients. Levels of IL8 secretion by colonic biopsies from 
patients with active Crohn’s disease (CD), active ulcerative colitis (UC) and from 
healthy controls (HC), in the presence (+PS) or absence (-PS, live bacteria) of 
antibiotic mixture. Statistical significances are denoted using alphabetical letters 
(bP < 0.01). 
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Figure 6  Representative trend of cytokine secretion after muramyl dipeptide 
stimulation, with antibiotics. Variation trend of IL8 secretion after muramyl 
dipeptide (MDP) stimulation in patients suffering from active Crohn’s disease 
(CD), active ulcerative colitis (UC) and healthy controls (HC), in presence of 
antibiotics (+PS). No statistical significance was found. 
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Figure 5  Representative trend of cytokine secretion after muramyl dipeptide 
stimulation, with live bacteria. Variation trend of IL6 secretion after muramyl 
dipeptide (MDP) stimulation in patients suffering from active Crohn’s disease 
(CD), active ulcerative colitis (UC) and healthy controls (HC), in absence of 
antibiotics [live bacteria (LB)]. No statistical significance was found. 
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IL8 secretion. Thus, antibiotics alone seem to increase 
IL8 production in UC, either because of a loss of the 
protective effect of mucosal bacteria or for the release 
of pro-inflammatory bacterial compounds. Conversely, 
we observed a reduction of IL8 production in UC when 
MDP is used together with antibiotics. Even though 
there is no clear explanation for this phenomenon, we 
can argue that in this case antibiotics and MDP-induced 
peptides may synergize in controlling both protective 
and harmful bacteria[26].
We also showed that subjects with CD seem to 
have a lowered production of IL8 in response to MDP 
in the presence of LB. Although it is not clear whether 
defects in NOD2 signaling might play a role in this 
finding, these results support the idea that CD is not 
usually associated with a hyper-inflammatory response 
to MDP, i.e., it is not just an autoinflammatory disorder. 
Recent data suggest that inflammation in CD may 
be the result of compensatory responses to defective 
immunity[27].
Although it was not the primary aim of our work, 
we could demonstrate that culture with antibiotics 
is the only ex vivo condition in which it was possible 
to identify profiles of cytokine secretions able to 
discriminate between CD and UC with good sensitivity 
and specificity. Indeed, the combination of measures 
of G-CSF, TNFα, IL4 and IL17 was shown to identify 
CD with respect to UC with sensitivity and specificity 
respectively of 92% and 50%. Rather than being used 
to assist diagnosis, which relies only on clinical and 
histological features, these results highlight once more 
the importance of taking into account the presence of 
mucosal bacteria when dealing with ex vivo analyses 
of IBD.
Among the limitations of this study, we need to 
mention the small sample size. The decision not to 
apply corrections to the p values for significance for 
multiple univariate comparisons was a consequence of 
this constrain and it should be taken into account. 
However, despite the small sample size, valid 
results have been obtained with this ex vivo mucosal 
culture, that allowed us to discern the two IBD forms.
In conclusion, we showed that CD and UC have 
distinct cytokine profiles in the intestinal mucosa 
and that the mucosal-associated microbiota can 
differentially impact on the inflammatory response in 
the two conditions.
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Background
Inflammatory bowel diseases (IBD) are associated with an unbalanced crosstalk 
between the mucosal immune system and the luminal content. Production 
of cytokines and antimicrobial-peptides in gut mucosa may contribute to the 
shaping of an altered intestinal microbiota and, conversely, microbes can 
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Figure 7  Multivariate combinations. A: Roc curve of IL2, IL4 and IL8: the best cutoff value was for a sensitivity of 100% and specificity of 71% to discriminate IBD (UC 
and CD) from healthy controls (AUC = 0.98, 95%CI: 0.93-1.00); B: Roc curve of MCP1, IL8 and IL10: the best cutoff value was for a sensitivity of 94% and specificity 
of 75% to discriminate IBD (UC and CD) from healthy controls (AUC = 0.91, 95%CI: 0.79-1.00); C: Roc curve of G-CSF, TNFα, IL4 and IL17: the best cutoff value was 
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translocate across the epithelium and induce an excessive inflammatory 
response and recruit adaptive immunity. Treatment of IBD with antibiotics, 
however, gave inconsistent results as different bacterial species may have 
protective or harmful effects. 
Research frontiers
Studies on the pathogenesis of IBD should involve the specific disease-
associated microbiota together with the mucosal immunity, with its genetic 
background. Thus, ex vivo experiments that bring together these two factors 
are of particular importance to unravel the pathogenesis of IBD. 
Innovations and breakthroughs
By reproducing four different conditions, we could dissect the effect of disease-
associated live or antibiotic-inactivated bacteria on the mucosal response to 
muramyl dipeptide (MDP). We showed that live bacteria affect the response to 
MDP in different ways in Crohn’s disease (CD) and in ulcerative colitis (UC).
Applications
Ex vivo analyses of the inflammatory response in the presence of antibiotics 
and soluble stimuli may allow studying the action of different antibiotics in 
patients with CD or UC. 
Terminology
MDP represents a pro-inflammatory stimulus used to mimic the inflammatory 
activation.
Peer-review
Some strengths of the article include: an adequate sample to test the 
hypothesis, novel study looking at the autochthonous colonization of the 
intestinal mucosa by the disease-associated microbiota, and seemingly good 
methods to address the question. It also provides a novel method to identify CD 
and UC based off of specific cytokines markers. 
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